All In Biotech

Drug Trial Radar · NCT04951713

Effect of Clarithromycin and Rifampicin on the Pharmacokinetics of XZP-3287 in Healthy Subjects

A Single-center, Open-label, Drug-drug Interaction Study of XZP-3287 Tablets in Healthy Subjects

Last checked: Nov 20, 2026Latest source record: Jul 27, 2021 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknown

Status

Status unknown

Enrollment

60

Planned (sponsor's estimate)

Start

Jul 2021

Primary completion

Sep 2021

Study completion Dec 2021

Sponsor

Sponsor type
Industry
First posted
Jul 7, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This is a phase I study to assess the drug-drug interaction of XZP-3287 and Clarithromycin/Rifampicin. The study also evaluates the pharmacokinetic and tolerability of XZP-3287 in healthy subjects.

Conditions

  • Healthy

Interventions

  • XZP-3287 combined with clarithromycinDrug

    Drug: XZP-3287, oral, 120 mg once daily for day 1 and day 12 Drug: clarithromycin, oral, 500 mg twice daily for day 8 to day 21

  • XZP-3287 combined with rifampicinDrug

    Drug: XZP-3287, oral, 360 mg once daily for day 1 and day 14 Drug: rifampicin, oral, 600 mg once daily for day 8 to day 19

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Primary PK EndpointsTime frame: day 1~day 20/day22
  2. Primary PK EndpointsTime frame: day 1~day 20/day22
  3. Primary PK EndpointsTime frame: day 1~day 20/day22

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • The First Affiliated Hospital of Bengbu Medical College

    Bengbu, Anhui, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.